- Home
- SABS vs ERNA Comparison
SABS vs ERNA Comparison
Compare SABS & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- ERNA
- Stock Information
- Founded
- SABS 2014
- ERNA 2018
- Country
- SABS United States
- ERNA United States
- Employees
- SABS N/A
- ERNA N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- SABS Health Care
- ERNA Health Care
- Exchange
- SABS Nasdaq
- ERNA Nasdaq
- Market Cap
- SABS 15.8M
- ERNA 13.5M
- IPO Year
- SABS N/A
- ERNA N/A
- Fundamental
- Price
- SABS $2.75
- ERNA $1.96
- Analyst Decision
- SABS Strong Buy
- ERNA
- Analyst Count
- SABS 5
- ERNA 0
- Target Price
- SABS $11.80
- ERNA N/A
- AVG Volume (30 Days)
- SABS 37.3K
- ERNA 86.4K
- Earning Date
- SABS 08-07-2025
- ERNA 08-12-2025
- Dividend Yield
- SABS N/A
- ERNA N/A
- EPS Growth
- SABS N/A
- ERNA N/A
- EPS
- SABS N/A
- ERNA N/A
- Revenue
- SABS $377,835.00
- ERNA $535,000.00
- Revenue This Year
- SABS N/A
- ERNA N/A
- Revenue Next Year
- SABS N/A
- ERNA N/A
- P/E Ratio
- SABS N/A
- ERNA N/A
- Revenue Growth
- SABS N/A
- ERNA 365.22
- 52 Week Low
- SABS $1.00
- ERNA $1.75
- 52 Week High
- SABS $5.01
- ERNA $35.10
- Technical
- Relative Strength Index (RSI)
- SABS 75.33
- ERNA 44.27
- Support Level
- SABS $2.31
- ERNA $1.88
- Resistance Level
- SABS $2.98
- ERNA $2.13
- Average True Range (ATR)
- SABS 0.24
- ERNA 0.12
- MACD
- SABS 0.09
- ERNA 0.05
- Stochastic Oscillator
- SABS 89.31
- ERNA 81.08
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.